Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2011 Apr 28

PMID 21521777

Citations 32

Authors

Miriam E Mossoba

Masanori Onda

Justin Taylor

Paul R Massey

Shirin Treadwell

Elad Sharon

Raffit Hassan

Ira Pastan

Daniel H Fowler

Affiliations

Soon will be listed here.

Abstract

Purpose: The success of immunotoxin therapy of cancer is limited by host production of neutralizing antibodies, which are directed toward the Pseudomonas exotoxin A (PE) component. In this proof-of-principle study using a well-established murine model, we hypothesized that a newly developed immune depletion regimen consisting of pentostatin plus cyclophosphamide would abrogate anti-immunotoxin reactivity.

Experimental Design: BALB/c hosts were injected weekly with recombinant immunotoxin (RIT) SS1P, which is an antimesothelin Fv antibody fragment genetically fused to a 38 kDa portion of PE, and has been evaluated in clinical trials. Experimental cohorts received induction chemotherapy consisting of pentostatin (P) plus cyclophosphamide (C) prior to initial RIT exposure; some cohorts received further maintenance PC therapy of varying intensity just prior to each weekly RIT challenge. Cohorts were monitored for T, B, myeloid cell depletion, and for total anti-SS1P antibody (Ab) formation.

Results: Controls uniformly developed anti-SS1P Ab after the third RIT exposure. Induction PC therapy reduced the frequency of hosts with anti-SS1P Ab. Abrogation of antibody generation was improved by maintenance PC therapy: nearly 100% of recipients of intensive PC maintenance were free of anti-SS1P Ab after 9 weekly RIT doses. The most effective PC regimen yielded the greatest degree of host B-cell depletion, moderate T-cell depletion, and minimal myeloid cell depletion.

Conclusions: Induction and maintenance PC chemotherapy safely prevented anti-immunotoxin antibody formation with uniform efficacy. These data suggest that immunotoxin therapy might be used in combination with pentostatin plus cyclophosphamide chemotherapy to improve the targeted therapy of cancer.

Citing Articles

Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?.

Borea F, Franczak M, Garcia M, Perrino M, Cordua N, Smolenski R Int J Mol Sci. 2023; 24(11).

PMID: 37298116 PMC: 10253134. DOI: 10.3390/ijms24119165.

A potent tumor-selective ERK pathway inactivator with high therapeutic index.

Zuo Z, Liu J, Sun Z, Silverstein R, Zou M, Finkel T PNAS Nexus. 2022; 1(3):pgac104.

PMID: 35899070 PMC: 9308561. DOI: 10.1093/pnasnexus/pgac104.

Antibody-Based Approaches to Target Pancreatic Tumours.

Sorbara M, Cordelier P, Bery N Antibodies (Basel). 2022; 11(3).

PMID: 35892707 PMC: 9326758. DOI: 10.3390/antib11030047.

Advances on Delivery of Cytotoxic Enzymes as Anticancer Agents.

Asrorov A, Muhitdinov B, Tu B, Mirzaakhmedov S, Wang H, Huang Y Molecules. 2022; 27(12).

PMID: 35744957 PMC: 9230553. DOI: 10.3390/molecules27123836.

Translational development of a tumor junction opening technology.

Kim J, Li C, Wang H, Kaviraj S, Singh S, Savergave L Sci Rep. 2022; 12(1):7753.

PMID: 35562182 PMC: 9094124. DOI: 10.1038/s41598-022-11843-z.

References

Weiss M, Maslak P, Jurcic J, Scheinberg D, Aliff T, Lamanna N . Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003; 21(7):1278-84. DOI: 10.1200/JCO.2003.08.100. View

Gao J, Kou G, Wang H, Chen H, Li B, Lu Y . PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity. Breast Cancer Res Treat. 2008; 115(1):29-41. DOI: 10.1007/s10549-008-0043-0. View

Hansen J, Weldon J, Xiang L, Beers R, Onda M, Pastan I . A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother. 2010; 33(3):297-304. PMC: 7291874. DOI: 10.1097/CJI.0b013e3181cd1164. View

Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E . Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001; 19(2):376-88. DOI: 10.1200/JCO.2001.19.2.376. View

Onda M, Willingham M, Nagata S, Bera T, Beers R, Ho M . New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res. 2005; 11(16):5840-6. DOI: 10.1158/1078-0432.CCR-05-0578. View

Georges G, Storb R . Review of "minitransplantation": nonmyeloablative allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2003; 77(1):3-14. DOI: 10.1007/BF02982597. View

Spiers A, Parekh S, Bishop M . Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin). J Clin Oncol. 1984; 2(12):1336-42. DOI: 10.1200/JCO.1984.2.12.1336. View

Pastan I, Hassan R, Fitzgerald D, Kreitman R . Immunotoxin therapy of cancer. Nat Rev Cancer. 2006; 6(7):559-65. DOI: 10.1038/nrc1891. View

Kreitman R, Hassan R, Fitzgerald D, Pastan I . Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009; 15(16):5274-9. PMC: 2754261. DOI: 10.1158/1078-0432.CCR-09-0062. View

10.

Bolanos-Meade J, Jacobsohn D, Margolis J, Ogden A, Wientjes M, Byrd J . Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005; 23(12):2661-8. DOI: 10.1200/JCO.2005.06.130. View

11.

Kreitman R, Squires D, Stetler-Stevenson M, Noel P, Fitzgerald D, Wilson W . Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005; 23(27):6719-29. DOI: 10.1200/JCO.2005.11.437. View

12.

Mitchell B, Mejias E, Daddona P, Kelley W . Purinogenic immunodeficiency diseases: selective toxicity of deoxyribonucleosides for T cells. Proc Natl Acad Sci U S A. 1978; 75(10):5011-4. PMC: 336252. DOI: 10.1073/pnas.75.10.5011. View

13.

Hershfield M, Buckley R, Greenberg M, Melton A, Schiff R, Hatem C . Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med. 1987; 316(10):589-96. DOI: 10.1056/NEJM198703053161005. View

14.

Chowdhury P, Viner J, Beers R, Pastan I . Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc Natl Acad Sci U S A. 1998; 95(2):669-74. PMC: 18478. DOI: 10.1073/pnas.95.2.669. View

15.

Miller K, Roberts T, Chan G, Schenkein D, Lawrence D, Sprague K . A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease. Bone Marrow Transplant. 2004; 33(9):881-9. DOI: 10.1038/sj.bmt.1704454. View

16.

Mariotti J, Foley J, Ryan K, Buxhoeveden N, Kapoor V, Amarnath S . Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood. 2008; 112(12):4765-75. PMC: 2597142. DOI: 10.1182/blood-2008-05-154278. View

17.

Giralt S, Khouri I, Champlin R . Non myeloablative "mini transplants". Cancer Treat Res. 2000; 101:97-108. View

18.

Mariotti J, Taylor J, Massey P, Ryan K, Foley J, Buxhoeveden N . The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. Biol Blood Marrow Transplant. 2010; 17(5):620-31. PMC: 3061246. DOI: 10.1016/j.bbmt.2010.11.029. View

19.

Kreitman R, Wilson W, Bergeron K, Raggio M, Stetler-Stevenson M, Fitzgerald D . Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001; 345(4):241-7. DOI: 10.1056/NEJM200107263450402. View

20.

Filpula D, Yang K, Basu A, Hassan R, Xiang L, Zhang Z . Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem. 2007; 18(3):773-84. DOI: 10.1021/bc060314x. View